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IMPORTANCE Mechanical thrombectomy (MT) improves clinical outcomes in patients with
acute ischemic stroke (AIS) caused by a large vessel occlusion. However, it is not known
whether intravenous thrombolysis (IVT) is of added benefit in patients undergoingMT.
OBJECTIVE To examine whether treatment with IVT before MTwith a stent retriever is
beneficial in patients undergoingMT.
DESIGN, SETTING, AND PARTICIPANTS This post hoc analysis used data from 291 patients
treated with MT included in 2 large, multicenter, prospective clinical trials that evaluatedMT
for AIS (Solitaire With the Intention for Thrombectomy performed from January 1, 2010,
through December 31, 2011, and Solitaire Flow Restoration Thrombectomy for Acute
Revascularization from January 1, 2010, through December 31, 2012). An independent core
laboratory scored the radiologic outcomes in each trial.
INTERVENTIONS Patients were treated with IVT with tissue plasminogen activator followed
byMT (IVT andMT group) with the use of a stent retriever or MTwith a stent retriever alone
(MT group).
MAIN OUTCOMES ANDMEASURES Successful reperfusion, functional independence (modified
Rankin Scale score of 0-2) andmortality at 90 days, symptomatic intracranial hemorrhage,
emboli to new territory, and vasospasmwere compared.
RESULTS Of 291 patients included in the analysis, 160 (55.0%) underwent IVT andMT (mean
[SD] age, 67 [13] years; 97 female [60.6%]), and 131 (45.0%) underwent MT alone (mean [SD]
age, 69 [12] years; 71 [55.7%] female). Median Alberta Stroke Program Early CT Score at
baseline was lower in the IVT andMT group (8 vs 9, P = .04). There was no statistically
significant difference in the duration from symptom onset to groin puncture (254minutes for
the IVT andMT group vs 262minutes for the MT group, P = .10). The number of passes, rate
of successful reperfusion, functional independence at 90 days, mortality at 90 days, and
emboli to new territory were also similar among groups. Symptomatic intracranial
hemorrhage (1% vs 4%) and parenchymal hemorrhages type 1 (1% vs 3%) or type 2 (1% vs
2%) did not differ significantly (P = .25). Vasospasm occurredmore often in patients who
received IVT andMT vsMT alone (27% vs 14%, P = .006). In multivariate analysis, no
statistically significant association was observed between IVT andMT vsMT alone for any of
the outcomes.
CONCLUSIONS AND RELEVANCE The results indicate that treatment of patients experiencing
AIS due to a large vessel occlusion with IVT before MT does not appear to provide a clinical
benefit over MT alone. A randomized clinical trial seems warranted.
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F ive randomized trialspublished in2015haveproventhatmechanical thrombectomy(MT)witha stent retriever incombinationwith intravenous thrombolysis (IVT) is su-
perior to IVT alone in patients experiencing acute ischemic
stroke (AIS) caused by large vessel occlusion in the anterior
circulation.1-6 Before these studies,1-6 IVT with tissue plas-
minogenactivator (tPA)was theonly reperfusion therapywith
aprovenbenefitonclinicaloutcomeinpatientswithAIS.7Over-
all, 85% of patients included in the MT trials received IVT be-
fore randomization for MT.1-5 However, of those randomized
to subsequent MT without follow-up computed tomographic
angiography after IVT, only a small proportion of patients had
vesselpatencyat the timeof the first catheterangiography, sug-
gesting that early recanalization in response to IVT is uncom-
mon in this selected patient population with a proximal
occlusion.3Despite the lowfrequencyofearly reperfusionwith
IVT alone, IVT could positively influence the clinical outcome
after MT. For instance, by enhancing the fibrinolytic process,
IVT could increase the speed and likelihood of successful rep-
erfusionwithMT, reduce the required number of passes with
a stent retriever, anddecrease the frequency ofmicrovascular
thrombosis.8,9 Moreover, achieving recanalization is not al-
wayspossiblewithMT,andsuchpatientsmaystill benefit from
IVT. Finally, in some patients, especially those with distal oc-
clusions, IVT alone may result in recanalization, averting the
need for MT altogether. On the other hand, IVT may increase
theriskofhemorrhagiccomplications7,10andresult in fragmen-
tationof the thrombus,potentially reducing theefficacyofMT
in achieving complete reperfusion of distal vessels. In addi-
tion, use of IVTmay cause a delay of the start of theMTproce-
dure, especially ifpatientsare first admitted toaprimarystroke
center and transferred to a comprehensive stroke center only
after a large vessel occlusionhas been established. Finally, IVT
is a costly therapy, especially in the United States.11
Adirect comparisonbetweenMTafter IVTvsMTalonehas
notbeenstudied inarandomizedclinical trial todate.Wethere-
foreperformedaposthoc analysis fromapooleddata set from
2 large prospective clinical trials with independent neuroim-
aging assessment to determine the role of IVT in the treat-
mentofpatientswithAIS causedbyaproximal largevessel oc-
clusion who were treated with MT.
Methods
Study Design and Population
Weperformedapatient-level, pooled, post hoc analysis of the
Solitaire With the Intention for Thrombectomy (SWIFT) and
Solitaire FlowRestorationThrombectomy forAcuteRevascu-
larization (STAR) studies. The designs of both these multi-
center, prospective clinical trial studies have been reported
previously.12,13 Briefly, both studies12,13 includedpatientswith
AIS caused by a large vessel proximal arterial occlusion. In
SWIFT, patients were randomized between MT with a Soli-
taireFRstent retriever (MedtronicNeurovascular) or theMerci
device (Stryker Neurovascular).
This study had a roll-in phase in which all patients were
treated with a stent retriever. This roll-in cohort was in-
cluded in the current study.Weexcludedpatients treatedwith
theMerci devicebecause this doesnot represent current clini-
cal practice. STAR was a single-arm study in which all in-
cluded patients underwentMTwith the Solitaire FR stent re-
triever. In both SWIFT and STAR, patients were eligible if MT
was feasible within 8 hours of symptom onset. Intravenous
thrombolysiswasrecommendedinallpatientswithin4.5hours
of stroke symptom onset who did not have any contraindica-
tion for IVT. In thosenot treatedwith IVT, theexact reasonwas
not recorded in the case report form. To provide some insight
into the possible reasons for withholding IVT, an overview of
absoluteandrelativecontraindications to IVTisprovided.Clini-
caloutcomewasevaluatedat90-dayfollow-upusing themodi-
fied Rankin Scale (mRS). SWIFT was active from January
1, 2010, throughDecember 31, 2011, andSTAR fromJanuary 1,
2010, throughDecember 31, 2012. SWIFTwas situatedmainly
in theUnited States and STAR inEurope, Canada, andAustra-
lia.The local ethics committeeat every site approved thestudy
protocol and informed consent form, and all patients or their
legal representatives provided written informed consent.
The imagingdata in STARandSWIFTwere adjudicatedby
independentcore laboratories.Clinicaloutcomeswerenotcen-
trally adjudicated across the 2 trials. Variables scored by the
core laboratories were location of the occlusion, final reper-
fusion grades, andhemorrhagic complications. In SWIFT, the
assessors were masked to allocation of the patient.
MTProcedure
The aim of the MT procedure in STAR and SWIFT was to
achieve successful reperfusion of the territory of the
occluded vessel as fast as possible. The use of a balloon guide
catheter was mandatory, and rescue therapy with a different
thrombectomy device or intra-arterial chemical thrombolysis
was allowed if deemed necessary by the interventionalist.
Follow-up brain imaging was performed after 24 hours in all
patients.
Statistical Analysis
We compared patients who underwent MT after treatment
with IVT to those who underwent MT alone. Successful
Key Points
Question Is intravenous thrombolysis of added benefit to
patients with acute ischemic stroke undergoingmechanical
thrombectomy?
Findings This post hoc analysis used data from 291 patients
treated with mechanical thrombectomy included in 2 large
multicenter clinical trials; 55% received intravenous thombolysis in
addition to mechanical thrombectomy, and 45% underwent only
mechanical thrombectomy. After adjustment for potential
confounders, no difference was found between the 2 groups in
any of the clinical or radiologic outcomes studied.
Meaning This study found no apparent benefit of intravenous
thrombolysis to patients with ischemic stroke undergoing
mechanical thrombectomy.
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reperfusionwas defined as amodified Thrombolysis in Cere-
bral Infarction (mTICI) score of 2b or higher at the end of
the procedure. We also analyzed separately the differences
in mTICI 3 reperfusion between the groups because pre-
treatmentwith IVTcould influence the frequencyof small dis-
tal emboli. Symptomatic intracranial hemorrhage (sICH) was
defined as any hemorrhage within 24 hours associated with
an increase of 4 points or more on the National Institutes of
Health Stroke Scale (NIHSS) or that resulted in death.
Categoricalvariableswerecomparedbetweengroupsusing
aFisher exact test. Continuousvariableswere comparedusing
a t test,exceptinthecasewheremediansandinterquartileranges
are reported, inwhichcaseaWilcoxon ranksumtestwasused.
Using multivariate logistic regression analysis, we examined
whether the use of IVTwas associated with technical aspects,
complication rate, or outcome afterMT. The following clinical
outcomeswereincludedasdependentvariablesinseparatemod-
els:mRSscoreof0 to2 (goodclinical outcomes),mRSscoresof
0 to 1 (excellent outcomes), andmortality at 90-day follow-up.
In thesemodels,weadjusted for age, sex,NIHSS score,Alberta
StrokeProgramEarlyCTScore (ASPECTS), locationofocclusion,
atrial fibrillation, diabetes, site of recruitment, and time from
symptomonset tohospital arrival.Todetermineanassociation
with technical aspects of the procedure and safety end points,
weusedthefollowingparametersasdependentvariables:more
than 2 passes with stent retriever, mTICI 2b or 3 reperfusion,
mTICI3 reperfusion, sICH,emboli touninvolvedterritory,atrial
fibrillation,diabetes,siteofrecruitment,andvasospasm.Finally,
foranassociationwithprocedural times,weusedasdependent
variablestimefromhospitalarrival togroinpunctureof lessthan
90minutesand time fromgroinpuncture to reperfusionof less
than 45 minutes. These models were adjusted for age, sex,
NIHSS score, ASPECTS, location of occlusion, atrial fibrilla-
tion, diabetes, site of recruitment, and time from symptom
onset to hospital arrival. In a sensitivity analysis, we ran all
multivariate analyses excluding patients who received
bridging-dose tPA. SAS statistical software, version 9.1 (SAS
Institute Inc), was used for analysis. Statistical significance
was defined as 2-sided P < .05.
Results
In total, 346patientswereenrolled inSWIFT(n = 144)andSTAR
(n = 202) (Figure). Fifty-five patients from SWIFT random-
ized to treatment with the Merci device were excluded from
the analysis. Of the remaining 291 patients, 160 (55.0%) un-
derwentMTafter IVT (mean [SD] age, 67 [13] years; 97 female
[60.6%]), and 131 (45.0%) were treated with MT alone (mean
[SD] age, 69 [12] years; 71 [55.7%] female). Of thepatientswho
received IVT, IVT failed in 116 (full tPA dose), and 44 received
bridging therapy. The mean tPA dose in patients who re-
ceived bridging therapy was 0.62 mg/kg. The contraindica-
tions for IVT in patients who were treated with MT alone are
reported in Table 1. Overall, 117 patients (89.3%) who did not
receive IVT had at least one contraindication.
The baseline characteristics are provided in Table 2. Pa-
tientswho received IVT andMThad a lower frequency of car-
dioembolic stroke attributable to atrial fibrillation (53 [33.1%]
vs 62 [47.3%],P = .02) anddiabetes (22 [13.8%] vs 32 [24.4%],
P = .02) andhad lowermedianASPECTS (8vs9,P = .04) com-
pared with patients who were treated with MT alone. No dif-
ferenceswere found inmedianNIHSSscores (17 inbothgroups)
or occlusion location between groups. Differences in base-
line variables between patients included in SWIFT and STAR
are provided in eTable 1 in the Supplement. A comparison of
baseline characteristics, procedure details, and outcome be-
tween patients who received full-dose tPA and those who re-
ceived bridging-dose tPA is given in eTables 2 and 3 in the
Supplement.
Details of theMTprocedure andclinical outcomesarepre-
sented inTable3.Themediantimefromsymptomonset tohos-
pital arrival was shorter in patients treated with IVT and MT
(171 vs 190 minutes, P = .04), but the median time from hos-
pital arrival to groin puncture was similar in both groups (79
vs 77minutes, P = .46). No differenceswere found in theme-
dian number of passes (1 for both groups) or the rate ofmTICI
2bor 3 reperfusion (127 [84.1%]vs 105 [84.7%]) amonggroups.
Vasospasmoccurredmore often in patientswho received IVT
andMT(43 [26.9%]vs 18 [13.7%],P = .006).Wefoundthat sICH
occurred less frequently in patients treated with IVT and MT
(2 [1.3%] vs 5 [3.8%], P = .25), but the difference was not sta-
tistically significant. Frequency of other types of ICH was as
follows: parenchymal hemorrhage type 1, 1 (0.6%) vs 4 (3.1%);
parenchymal hemorrhage type 2, 1 (0.6%) vs 2 (1.5%); hemor-
rhagic infarct 1, 29 (18.1%) vs 25 (19.1%); hemorrhagic infarct
2, 19 (11.9%) vs 11 (8.4%); and subarachnoid hemorrhage, 2
(1.3%) vs 4 (3.1%). None of these differed significantly be-
tween groups (Table 3).
Results of the multivariate analyses are presented in
Table 4. We did not find a statistically significant association
between theuseof IVTandanyof theoutcomesstudied.There
was a lower risk of sICH (adjusted odds ratio [OR], 0.03; 95%
CI, 0.00-1.28), a higher risk of emboli to uninvolved territory
Figure. Flowchart of Patient Selection
346 Patients
144 SWIFT
202 STAR
116 IVT failures 44 Bridging therapy
160 IVT and MT
291 Study cohort
55 Patients treated with
Merci device
131 Only MT
A total of 346 patients were enrolled in the Solitaire With the Intention for
Thrombectomy (SWIFT) (n = 144) and Solitaire Flow Restoration
Thrombectomy for Acute Revascularization (STAR) (n = 202) clinical trial
studies, of whom 55 patients were excluded from the analysis because they
were not treated with the Solitaire FR (flow restoration) stent retriever. The
remaining 291 patients comprised the analysis population.
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(adjusted OR, 4.12; 95% CI, 0.75-22.54), and a higher rate of
functional independence (90-daymRS score of 0-2: adjusted
OR, 1.48; 95% CI, 0.80-2.74) in patients treated with IVT and
MT, although these findingswere not statistically significant.
Whenwe excluded patients who received bridging-dose tPA,
the results of the multivariate analysis were essentially the
same (eTable 4 in the Supplement).
Discussion
Usingdata from2large internationalprospectivestudies,weex-
aminedwhether treatmentofpatientswithAISwith IVTbefore
endovascular clot retrieval with the Solitaire FR stent retriever
isbeneficial or addsany risks to theprocedure.Our results indi-
cate that, after adjustment for confounders, the combination
of IVT and MT had no statistically significant benefit over MT
alone in terms of procedural, clinical, or safety outcomes.
Onlyafewstudies14-19havepreviouslyexamineddifferences
betweenendovascular therapycombinedwith IVTvsendovas-
cular treatment alone.Bhatia et al14 analyzeddata from157pa-
tients includedintheCalgaryStrokeProgrambetween2002and
2009.Theyobserveda trendtowardahigher rateof recanaliza-
tionanda lower rateof sICHamongpatients treatedwith intra-
arterial IVT compared with patients treated only with intra-
arterial therapy.Therewere important imbalancesregardingen-
dovascular techniqueandtimestotreatmentbetweengroups in
this study,whichmakethedatasomewhatdifficult to interpret.
Adifferentretrospective,single-centerstudy15alsofoundnodif-
ference between IVT andMTvsMTalone, but again this study
hadalimitedsamplesizeanddidnotadjustforconfoundingvari-
ables. A US phase 1 trial in which patients were randomized to
IVT or placebo in combination with intra-arterial therapy
found slightly higher recanalization rates among patients ran-
domized to IVT.16 This study included only 35 patients and
used intra-arterial thrombolysis instead of MT, making it no
longer clinically relevant. In a recent study, Broeg-Morvay and
colleagues17 used propensity score matching to compare 40
patients treatedwithMTwith 40 patients who underwentMT
Table 1. Contraindications for IVT
Contraindication
No. (%) of Patients
Undergoing MT without IVT
(n = 131)
Oral anticoagulation or INR >1.7 38/122 (31.1)
Symptom onset to hospital arrival >4 h 40/124 (32.3)
Systolic blood pressure ≥185 mm Hg 11/129 (8.5)
Diastolic blood pressure ≥110 mm Hg 3/129 (2.3)
Glucose >400 mg/dL 1/126 (0.8)
Glucose <50 mg/dL 5/126 (4.0)
Platelets <100 × 103/μL 2/131 (1.5)
APTT >39 s 9/111 (8.1)
Prior stroke or TIA and diabetes 8/131 (6.1)
Abbreviations: APTT, activated partial thromboplastin time; INR, international
normalized ratio; IVT, intravenous thrombolysis; MT, mechanical
thrombectomy; TIA, transient ischemic attack.
SI conversion factors: To convert glucose tomillimoles per liter, multiply by
0.0555; platelets to 109/L, multiply by 1.
Table 2. Baseline Characteristics of the Study Patientsa
Characteristic
MT and IVT
(n = 160)
MT Alone
(n = 131) P Value
Age, mean (SD), y 67 (13) 69 (12) .14
Female 97/160 (60.6) 73/131 (55.7) .41
NIHSS, median (IQR) 17 (13-20) 17 (13-20) .86
Medical history
Atrial fibrillation 53/160 (33.1) 62/131 (47.3) .02
Hypertension 99/160 (61.9) 87/131 (66.4) .46
Diabetes 22/160 (13.8) 32/131 (24.4) .02
Hyperlipidemia 69/160 (43.1) 57/131 (43.5) >.99
Current smoker 21/160 (13.1) 19/131 (14.5) .74
Prior stroke or TIA 25/160 (115.6) 30/131 (22.9) .13
Antiplatelet use 37/160 (23.1) 40/131 (30.5) .18
Systolic blood pressure, mean (SD), mm Hg 145 (23) 147 (25) .49
Diastolic blood pressure, mean (SD), mm Hg 80 (15) 80 (15) .86
Left side occlusion 78/157 (49.7) 64/129 (49.6) >.99
ASPECTS, mean (SD) 8.1 (1.8) 8.5 (1.6) .03
ASPECTS, median (IQR) 8.0 (7.0-10.0) 9.0 (8.0-10.0) .04
Location of occlusion
Carotid 31/153 (20.3) 23/129 (17.8) .72
M1 99/153 (64.7) 88/129 (68.2)
M2 or M3 23/153 (15.0) 17/129 (13.2)
Posterior circulation 0/153 (0) 1/129 (0.8)
Serum glucose, mean (SD), mg/dL 126 (50) 130 (64) .56
Platelets, mean (SD), ×103/μL 228 (74) 239 (85) .23
Abbreviations: ASPECTS, Alberta
Stroke Program Early CT score;
IQR, interquartile range;
IVT, intravenous thrombolysis;
MT, mechanical thrombectomy;
NIHSS, National Institutes of Health
Stroke Scale; TIA, transient ischemic
attack.
SI conversion factors: To convert
glucose tomillimoles per liter,
multiply by 0.0555; platelets to
109/L, multiply by 1.
a Data are presented as number
(percentage) of patients unless
otherwise indicated.
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after treatment with IVT. They also did not find any statisti-
cally significant differences in functional outcome or risk of
sICH between the groups. However, unlike our study, they
observed a trend toward a lower risk of sICH in the MT alone
group. Weber et al18 reported data from 250 patients treated
with second-generation devices included in a retrospective,
single-center study. Of these, 105 received IVT and 145 under-
went MT alone. They did not find differences in successful
revascularization rates (TICI 2b or 3, 73.8% vs 73.1%; P = .95),
complications, or good clinical outcome (mRS scores of 0-2,
35.2% vs 40.0%; P = .44). In the MT alone group, 70 patients
were potentially eligible for IVT but did not receive it inten-
tionally. Comparing these patients with the 75 patients treated
with MT alone with a contraindication to IVT, the authors
found that the former group had better clinical outcomes
(48.6% vs 32.0%, P = .04). Finally, they reported workflow
measures showing shorter symptom onset to groin puncture,
first imaging to groin puncture, and symptom onset to end of
procedure in the MT alone group. A recent study by Leker et
al19 found that in patients treated with IVT and MT, fewer
stent retriever passes were required to achieve recanalization
than in patients who received MT alone. Although this find-
ing would be in line with the hypothesis that IVT facilitates
thrombus removal with MT, we could not confirm this obser-
vation. In our study, no difference was found in the median
number of passes between the 2 groups.
Subgroupanalyses in theMulticenterRandomizedClinical
Trial of Endovascular Treatment for Acute Ischemic Stroke in
theNetherlands(MRCLEAN),EndovascularTreatmentforSmall
CoreandProximalOcclusionIschemicStroke(ESCAPE),andEn-
dovascularRevascularizationWithSolitaireDeviceVersusBest
MedicalTherapy inAnteriorCirculationStrokeWithin8Hours
(REVASCAT)didnot suggest statistical heterogeneityof theef-
fect ofMTbetweenpatientswhodidordidnot receive IVT. In-
terestingly, in ESCAPE,MTwas associatedwith an increase in
mortality at 90 days in patients who did not receive IVT (20%
vs 13%), whereas among patientswho received IVT (aswell as
in the studyas awhole),MT resulted in adecrease inmortality
(7%vs21%).3 ForMRCLEAN,ananalysis ofmortality stratified
by IVTstatushasnotbeenpublished todate. InREVASCAT, the
effect sizeofMTwasslightlyhigher inpatientsnot treatedwith
IVTbutwithout statisticalheterogeneity.5Thesubgroupanaly-
ses in these studies,however,were restrictedbyasmall sample
size: only 30patients (13%) inMRCLEAN, 45patients (27%) in
ESCAPE, and 33 patients (32%) in REVASCAT underwent MT
without IVT.The subgroupanalyseswere alsonot adjusted for
casemix.Theadditional valueof IVTcouldnotbeexamined in
the Extending the Time for Thrombolysis in Emergency Neu-
rological Deficits–Intra-arterial (EXTEND-IA) and Solitaire FR
With the Intention for Thrombectomy as Primary Endovascu-
larTreatmentforAcuteIschemicStroke(SWIFTPRIME)because
treatmentwith IVTwasmandatory for inclusion in these trials.
Table 3. Details of Procedural, Clinical, and Safety Outcomesa
Variable
MT and IVT
(n = 160)
MT Alone
(n = 131) P Value
Times, median (IQR), min
Symptom onset to hospital arrival 171 (75-245) 190 (108-274) .04
Symptom onset to groin puncture 254 (195-305) 262 (201-375) .10
Hospital arrival to groin puncture 79 (49-111) 77 (54-120) .46
Symptom onset to reperfusion 308 (253-361) 315 (242-424) .15
No. of passes with stent retriever, mean (SD) 1.7 (0.9) 1.8 (1.0) .28
No. of passes with stent retriever, median (range) 1 (1-5) 1 (1-7) .30
mTICI 2b or 3 reperfusion 127/151 (84.1) 105/124 (84.7) >.99
mTICI 3 86/151 (57.0) 66/124 (53.2) .54
Rescue therapy 20/160 (12.5) 17/131 (13.0) >.99
Complications
Emboli to uninvolved territory 7/156 (4.5) 3/126 (2.4) .52
Device-related serious adverse events 8/160 (5.0) 8/131 (6.1) .80
Vasospasm 43/160 (26.9) 18/131 (13.7) .006
sICH 2/160 (1.1) 5/131 (3.8) .25
SAH 2/160 (1.1) 4/131 (3.1) .41
PH1 1/160 (0.6) 4/131 (3.1) .18
PH2 1/160 (0.6) 2/131 (1.5) .59
HI1 29/160 (18.1) 25/131 (19.1) .88
HI2 19/160 (11.9) 11/131 (8.4) .44
Remote ICH 1/160 (0.6) 0/131 (0) >.99
Vessel perforation 0/160 (0) 1/131 (0.8) .45
Groin hematoma 3/160 (1.9) 2/131 (1.5) >.99
Outcome at 90 d
mRS score of 0-1b 65/156 (41.7) 46/128 (35.9) .33
mRS score of 0-2b 90/156 (57.7) 61/128 (47.7) .10
Mortality 13/160 (8.1) 16/131 (12.2) .32
Abbreviations: HI, hemorrhagic
infarct; IQR, interquartile range;
IVT, intravenous thrombolysis;
mRS, modified Rankin Scale;
MT, mechanical thrombectomy;
mTICI, modified Thrombolysis in
Cerebral Infarction; PH1, parenchymal
hemorrhage type 1;
SAH, subarachnoid hemorrhage;
sICH, symptomatic intracranial
hemorrhage.
a Data are presented as number
(percentage) of patients unless
otherwise indicated.
b Scores of 0 to 1 indicate excellent
outcomes; 0 to 2, good outcomes.
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In a recent published pooled analysis of MR CLEAN, SWIFT
PRIME,EXTEND-IA,ESCAPE,andREVASCAT(HighlyEffective
ReperfusionEvaluated inMultipleEndovascularStrokecollabo-
ration),nodifferenceswere foundinclinicaloutcomesbetween
IVT andMT andMT alone.6
Oneof themain reasons touse IVT inpatientswithaproxi-
malocclusion is that itmay lead toearly recanalization, thereby
negating the requirement for MT. However, data from recent
trials suggest that such early recanalizationdoesnot occur of-
ten. In ESCAPE, only 8 of 165 patients (4.8%) randomized to
MT had TICI 2b or 3 on the first angiography run.3 These data
werenot stratified to IVT status, but even if all 8 patientswere
in the group that received IVT, theproportionof patientswith
early reperfusionwould still beonly6.7%. Similar resultswere
seen inMRCLEAN,where recanalizationwas found in8 (3.7%)
of 216 patients who underwent catheter angiography.2 Eight
otherpatients randomized toMTdidnotundergo catheter an-
giography because of clinical improvement. Again, assuming
the artery had recanalized in all these patients, the propor-
tion of patientswith early reperfusionwould still be less than
7%. Similar percentages of early reperfusion were observed
in REVASCAT and SWIFT PRIME.4,5 The chance of early
recanalization in response to IVT is dependent on the loca-
tion of the occlusion, with distal ICA occlusions responding
poorly compared with M2 or M3 occlusions.20,21 The fact that
IVT often results in reperfusion of the occluded vessel over
time was nicely illustrated in the ESCAPE study. In the con-
trol group, follow-up computed tomographic angiography
was performed in 138 patients after a median period of 7
hours after symptom onset. Among those treated with IVT,
recanalization was observed in approximately one-third of
patients compared with only 7% of patients not treated with
IVT.3 However, the clinical benefit of this late reperfusion is
unknown.
Strengths and Limitations
Strengths of our study include the large sample size, com-
pleteness of the data, and the use of independent adjudica-
tion committees. Several limitations also warrant comment.
First, patients were not randomized for the use of IVT.
Patients who underwent MT alone usually had a contraindi-
cation for IVT that may have affected their outcomes. We
adjusted for baseline imbalances in the multivariate analy-
ses, but still we cannot exclude the possibility of residual
confounders. Second, although imaging end points were
evaluated by an independent core laboratory in each trial,
these outcomes were not centrally adjudicated across the 2
trials. Third, although we did not observe any statistically
significant differences between the groups for any of the
outcomes, we cannot exclude the possibility that this is
attributable to the relatively small sample size. For instance,
the point estimate of functional outcome and the rate of
sICH were in favor of patients treated with MT and IVT, but
the wide CIs preclude us from drawing firm conclusions. The
finding that IVT was associated with a lower risk of ICH, a
somewhat counterintuitive observation, should especially
be interpreted with caution, given the low number of
patients with a sICH in either group. Fourth, not all patients
in the IVT and MT group were treated with the same tPA
dose. Approximately a quarter of these patients received
bridging-dose tPA (0.6 mg/kg), as used in the Interventional
Management of Stroke II study.22 A sensitivity analysis
Table 4. Multivariate Analyses
Variable
No. (%) of Patients OR (95% CI)
MT and IVT (n = 160) MT Alone (n = 131) Unadjusted Adjusted
Timesa
Hospital arrival to groin puncture ≤90 min 97/156 (62.2) 72/121 (59.5) 1.12 (0.69-1.82) 1.63 (0.83-3.21)
Groin puncture to reperfusion ≤45 min 82/152 (53.9) 59/118 (50.0) 1.17 (0.72-1.90) 1.31 (0.75-2.29)
Technical details of the MT procedureb
mTICI 2b or 3 127/151 (84.1) 105/124 (84.7) 0.96 (0.50-1.84) 0.68 (0.28-1.66)
mTICI 3 86/151 (57.0) 66/124 (53.2) 1.16 (0.72-1.87) 1.38 (0.76-2.51)
>3 Passes with stent retriever 30/132 (22.7) 30/120 (25.0) 0.88 (0.49-1.58) 0.90 (0.44-1.85)
Procedural complicationsb
sICH 2/160 (1.3) 5/131 (3.8) 0.32 (0.06-1.67) 0.03 (0.00-1.28)
Emboli to uninvolved territory 7/156 (4.5) 3/126 (2.4) 1.93 (0.49-7.61) 4.12 (0.75-22.54)
Vasospasm 40/160 (25.0) 17/131 (13.0) 2.24 (1.20-4.17) 1.41 (0.58-3.42)
Outcome at 90 dc
mRS scores of 0-2d 90/156 (57.7) 61/128 (47.7) 1.50 (0.94-2.40) 1.48 (0.80-2.74)
Mortality 13/160 (8.1) 16/131 (12.2) 0.64 (0.29-1.37) 0.90 (0.35-2.30)
Abbreviations: IVT, intravenous thrombolysis; mRS, modified Rankin Scale;
MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral
Infarction; OR, odds ratio; sICH, symptomatic intracranial hemorrhage.
a Adjusted for age, sex, National Institutes of Health Stroke Scale (NIHSS) score,
Alberta Stroke Program Early CT Score (ASPECTS), location of occlusion, atrial
fibrillation, diabetes, site of recruitment, and interval from symptom onset to
hospital arrival.
bAdjusted for age, sex, NIHSS score, ASPECTS, location of occlusion,
international normalized ratio, antiplatelet use, atrial fibrillation, diabetes, site
of recruitment, and systolic blood pressure.
c Adjusted for age, sex, NIHSS score, ASPECTS, location of occlusion, atrial
fibrillation, diabetes, site of recruitment, and interval from symptom onset to
hospital arrival.
d Scores of 0 to 2 indicate good outcomes.
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excluding patients treated with bridging-dose tPA essentially
revealed similar results. Fifth, roughly one-third of the
patients who did not received tPA did not have a contraindi-
cation for IVT. This finding reflects the fact that local treat-
ment protocols in some of the participating centers allowed
direct treatment with MT in patients who were eligible for
treatment with IVT.
Conclusions
Weobservednobenefit or harmof treatmentwith IVT andMT
comparedwithMTalone inpatientswithAISandaproximaloc-
clusion.Onthebasisof thesedata,webelievethatarandomized
clinical trial directly comparing both strategies iswarranted.
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